A Cell-Based Screening Assay for rRNA-Targeted Drug Discovery
ACS Infectious Diseases · 2024
DOI: 10.1021/acsinfecdis.4c00446 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, 2024. Verfasst von Sandra Story und 1 weiteren Autor:innen. Beteiligte Einrichtung: NUBAD, LLC, Greenville, South Carolina 29605, United States. Hauptthemen laut MEDLINE: Escherichia coli, Anti-Bacterial Agents, Aminoglycosides, Drug Discovery. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NUBAD, LLC, Greenville, South Carolina 29605, United States.
- Laboratory of Medicinal Chemistry, Department of Chemistry, Clemson University, Clemson, South Carolina 29634, United States.
ORCID-Profile: Dev P Arya
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Story, S., & Arya, D. P. (2024). A Cell-Based Screening Assay for rRNA-Targeted Drug Discovery. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00446
Vancouver
Story S, Arya DP. A Cell-Based Screening Assay for rRNA-Targeted Drug Discovery. ACS Infectious Diseases. 2024. doi:10.1021/acsinfecdis.4c00446
BibTeX
@article{Story2024,
author = {Story, Sandra and Arya, Dev P},
title = {A Cell-Based Screening Assay for rRNA-Targeted Drug Discovery},
journal = {ACS Infectious Diseases},
year = {2024},
doi = {10.1021/acsinfecdis.4c00446}
}
EUVIMED